EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease

Nikolaos G Dimitriou, Sven G Meuth, Elena H Martinez-Lapiscina, Philipp Albrecht, Til Menge iD

CNS Drugs · 2023-01 · 37 (1) · 69-92

DOI: 10.1007/s40263-022-00977-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 04.01.2023. Verfasst von Nikolaos G Dimitriou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic autoimmune demyelinating and neurodegenerative disease of the central nervous system with a wide variety of clinical phenotypes. In spite of the phenotypic classification of MS patients, current data provide evidence that diffuse neuroinflammation and neurodegeneration coexist in all MS forms, the latter gaining increasing clinical relevance in progressive phases. Given that the transition phase of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS) is not well defined, and widely accepted criteria for SPMS are lacking, randomised controlled trials (RCTs) specifically designed for the transition phase have not been conducted. This review summarizes primary and secondary analyses and reports derived from phase III prospective clinical RCTs listed in PubMed of compounds authorised through the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of MS. The best data are available for interferon beta-1a (IFNb-1a) subcutaneous (s.c.), IFNb-1b s.c., mitoxantrone and siponimod, the latter being the most modern compound with likely the best risk-to-effect ratio. Moreover, there is a labels discrepancy for many disease-modifying treatments (DMTs) between the FDA and EMA, which have to be taken into consideration when opting for a specific DMT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingHumansInterferon beta-1aInterferon-betaRecurrenceRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Substanzen

Interferon beta-1aInterferon-beta

Autor:innen und Institutionen

  • Department of Neurology, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Germany.
  • Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barce…
  • Office of Therapies for Neurological and Psychiatric Disorders, Human Medicines Division, European Medicines Agency, Amsterdam, The Netherlands.
  • Department of Neurology, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Germany. phil.albrecht@gmail.com.
  • Department of Neurology, Maria Hilf Clinic, Mönchengladbach, Germany. phil.albrecht@gmail.com.
  • Department of Neurology, LVR-Klinikum Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Til Menge

Förderung

  • Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts

Zitieren

APA

Dimitriou, N. G., Meuth, S. G., Martinez-Lapiscina, E. H., Albrecht, P., & Menge, T. (2023). Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease. CNS Drugs, 37(1), 69-92. https://doi.org/10.1007/s40263-022-00977-3

Vancouver

Dimitriou NG, Meuth SG, Martinez-Lapiscina EH, Albrecht P, Menge T. Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease. CNS Drugs. 2023;37(1):69-92. doi:10.1007/s40263-022-00977-3

BibTeX
@article{Dimitriou2023,
  author = {Dimitriou, Nikolaos G and Meuth, Sven G and Martinez-Lapiscina, Elena H and Albrecht, Philipp and Menge, Til},
  title = {Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease},
  journal = {CNS Drugs},
  year = {2023},
  volume = {37},
  number = {1},
  pages = {69--92},
  doi = {10.1007/s40263-022-00977-3}
}
Kostenlos starten →